Prospective collection of donor tissue and blood or leukapheresis product from patients with solid tumours to enable development of methods for the manufacturing of clonal neoantigen T cell products (cNeT).

Study ID: 36938
Short Title: ATX-MAP-001 Tissue Research Protocol
Trust Name: UHS
Recruitment Site: Southampton General Hospital
Disease Area: Lung cancer Skin Cancer Urology
Phase: N/A
Expected End Date: 28/02/2023
Postcode: SO16 6YD
Contact Name: Amanda Pattie
Contact Email: studysupport1and3.crnwessex@nihr.ac.uk
Active: Yes

Inclusion criteria, exclusion criteria and study summary

1. Patient must be at least 18 years old at the Screening Visit. 2. Patient has given informed consent to participate in the study. 3. Suspected or confirmed diagnosis of Non-Small Cell Lung Cancer, melanoma or renal cancer with either primary, recurrent or metastatic disease scheduled for surgical excision and/or collection of multiple tissue samples via image or device guided biopsy. 4. Haemoglobin ‚â• 10g/dL. 5. White cell count ‚â• 3 x 109/L. 6. Negative laboratory test for blood borne pathogens (see exclusion criterion 5).

1. The patient is an employee of Achilles Therapeutics. 2. Clinical status precludes surgical removal of, or collection of multiple biopsies from, accessible tumour tissue. 3. Inadequate peripheral venous access precluding collection of blood. 4. Known pregnancy. 5. Known/laboratory confirmed diagnosis of an infectious disease preventing inclusion of tissue into cell manufacturing suite. As a minimum, the patient will undergo specific screening for the following infections: HIV 1 and 2, HTLV I/II, Hepatitis B, Hepatitis C, Syphilis (Appendix 1). 6. Patients who are currently participating in a clinical trial involving an unlicensed medical product. 7. Any medical reason why, in the opinion of the investigator, the patient should not participate in this study.

-

Study MapList of studies

Accessibility tools

Return to header